LDL reduction: How low should we go and is it safe?

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 481-487

  Robinson, Jennifer G ^a  

^a Lipid Research Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CLARITHROMYCIN; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEFAZODONE; NELFINAVIR; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HEALTH CARE COST; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ILEUM BYPASS; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; MYOPATHY; OBESITY; PANCREATITIS; PATIENT SELECTION; PLEIOTROPY; PROTEINURIA; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MUSCULAR DISEASES; NIACIN; PROCETOFEN; RISK FACTORS; STROKE;

EID: 58249087727     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0076-3     Document Type: Article

References (47)

1. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366: 1267-1278.
2. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46: 1855-1862.
3. Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.
4. Smith SC Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular diseaseE 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113: 2363-2372
5. Robinson JG, Stone NJ: Identifying patients for aggressive cholesterol lowering: The risk curve concept. Am J Cardiol 2006, 98: 1405-1408.
6. Law M, Wald N, Morris J: Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy. Health Technol Assess 2003, 7: 1-94.
7. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352: 1425-1435.
8. Crestor (rosuvastatin calcium) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2007. Available at http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed February 2007.
9. Lipitor (atorvastatin calcium) [package insert]. New York, NY: Pfizer Inc.; 2007. Available at http://www.pfizer.com/files/products/ uspi_lipitor.pdf. Accessed June 2008.
10. Vytorin (simvastatin/ezetimibe) [package insert]. White-house Station, NJ, and Kenilworth, NJ: Merck-Schering Plough Pharmaceuticals; 2008. Available at http://www.vytorin.com/vytorin/shared/documents/ vytorin_pi.pdf. Accessed June 2008.
11. Jones PH, Davidson MH, Stein EA, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92: 152-160.
12. Robinson J, Davidson M: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006, 4: 461-476.
13. Advicor (extended-release niacin) [package insert]. Abbott Park, IL: Abbott Laboratories; 2007. Available at http://www.rxabbott.com/pdf/ advicor.pdf. Accessed June 2008.
14. Simcor (niacin extended-release/simvastatin) [package insert]. Abbott Park, IL: Abbott Laboratories; 2008. Available at http://rxabbott.com/ pdf/simcor_pi.pdf. Accessed May 5, 2008.
15. Welchol (colesevelam hydrochloride) [package insert]. Parsippany, NJ: Daiichi Sankyo; 2005. Available at http://www.welchol.com/pdf/ Welchol_PI.pdf. Accessed May 2008.
16. Wagner AM, Jorba O, Bonet R, et al.: Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003, 88: 3212-3217.
17. Athyros VG, Papageorgiou AA, Athyrou VV, et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25: 1198-1202.
18. Durrington PN, Tuomilehto J, Hamann A, et al.: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diab Res Clin Pract 2004, 64: 137-151.
19. Kastelein JJP, Akdim F, Stroes ESG, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358: 1431-1443.
20. Smilde TJ, van Wissen S, Awollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001, 357: 577-581.
21. Underhill HR, Yuan C, Zhao X-Q, et al.: Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155: 584.e1-584.e5.
22. Johnson HM, Douglas PS, Srinivasan SR, et al.: Predictors of carotid intima-media thickness progression in young adults: The Bogalusa Heart Study. Stroke 2007, 38: 900-905.
23. van Wissen S, Smilde TJ, Trip MD, et al.: Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005, 95: 264-266.
24. Robinson JG: Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res 2008, 2008: 891425.
25. Kastelein JJ, van der Steeg WA, Holme I, et al.: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117: 3002-3009.
26. Robinson JG, Davidson MH: Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. Future Lipidol 2007, 2: 285-301.
27. Ford ES, Ajani UA, Croft JB, et al.: Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356: 2388-2398.
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. National Cholesterol Education Panel [no authors listed]. Circulation 2002, 106: 3143-3421.
29. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357: 2109-2122.
30. Davidson M, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol 2007, 49: 1753-1762.
31. Knopp RH, Tsunehara C, Retzlaff BM, et al.: Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: A pilot study. Metabolism 2006, 55: 1697-1703.
32. Farnier M, Roth E, Gil-Extremera B, et al.: Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007, 153: 335.e1-335.e8.
33. Ziajka P: Role of low-density lipoprotein apheresis. Am J Cardiol 2005, 96(4 Suppl 1): 67-69.
34. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statinrelated adverse events: A meta-analysis. Clin Ther 2006, 28: 26-35.
35. Davidson A, Clark J, Glass L, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97(Suppl 1): 32C-43C.
36. Davidson MH: RoLuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004, 3: 547-557.
37. Kasiske B, Wanner C, O'Neil C: An assessment of statin safety by nephrologists. Am J Cardiol 2006, 97(8 Suppl A): 82C-85C.
38. Davidson MH, Maccubbin D, Stepanavage M, et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006, 97: 223-228.
39. Davidson MH, Ballantyne CM, Kerzner B, et al.: Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58: 746-755.
40. Ballantyne CM, Davidson MH, McKenney J, et al.: Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008, 101: 1428-1436.
41. Guyton JR, Bays HE: Safety considerations with niacin therapy. Am J Cardiol 2007, 99(6 Suppl 1): S22-S31.
42. Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co.; 2008. Available at http://www.merck.com/product/usa/ pi_circulars/z/zocor/zocor_pi.pdf. Accessed June 2008.
43. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering [no authors listed]. JAMA 1984, 251: 365-374.
44. Jacobson TA, Armani A, McKenney JM, Guyton JR: Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99(6 Suppl 1): S47-S55.
45. Law M, RuAnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97(8 Suppl 1): S52-S60.
46. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. The FIELD study investigators [no authors listed]. Lancet 2005, 366: 1849-1861.
47. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6 Suppl 1): S3-S18.